Biotech startups in Europe
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| bit.bio | Cambridge | Series D | $25.0M | 2026-11-04 |
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| Basecamp Research | London | Series C | $140.0M | 2026-09-23 |
| Biolevate | Paris | Series A | $34.4M | 2026-09-21 |
| Biorce | Barcelona | Series A | $52.0M | 2026-02-02 |
| Brainomix | Oxford | Series C | $6.5M | 2026-02-24 |
| WhiteLab Genomics | Paris | Series B | $26.0M | 2026-10-05 |
| Microbiotica | Cambridge | Series C | $47.9M | 2026-10-16 |
8 rows of the CSV in 5 of its 18 columns.
- The 2,201 biotech startups in Europe have raised $27.5B in total.
- 273 of them closed their most recent round in the last 12 months, $5.1B combined.
- The largest of those rounds is OMass Therapeutics' $310.0M Series C, dated October 2026.
- The most recent is SRTD Biotech's $35.2M seed round on 9 November 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 79 of them, more than any other fund.
- Health care is the most common other sector, with 1,562 companies (71%).
- 33% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 1 to 10 employees (50% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 2,201| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Cambridge, United Kingdom | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| Bioliberty | Bioliberty develops rehabilitation solutions for degenerative and traumatic conditions as a medtech start-up. | Biotech | Edinburgh, United Kingdom | Series A | $3.3M | 2026-11-02 | $17.4M | Innovate UK, Scottish Enterprise, Old College Capital +2 | 11 to 50 | 2020 |
| Onego Bio | Onego Bio produces egg protein through fermentation as a food ingredient. | Biotech | Helsinki, Finland | Series B | $28.0M | 2026-10-26 | $100.6M | European Innovation Council, Business Finland, Tesi +2 | 11 to 50 | 2022 |
| Cellbox Solutions | Cellbox Solutions provides logistics solutions for the global biomedical industry. | Biotech | Cologne, Germany | Series A | $1.7M | 2026-10-20 | $15.3M | European Innovation Council, Fraunhofer Venture, CK Venture Capital | 11 to 50 | 2017 |
| Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Cambridge, United Kingdom | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London, United Kingdom | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
| WhiteLab Genomics | WhiteLab Genomics builds digital tools that help gene and cell therapy companies develop drugs faster and cheaper. | Artificial intelligence | Paris, France | Series B | $26.0M | 2026-10-05 | $36.5M | Y Combinator, Omnes Capital | 11 to 50 | 2019 |
| Aptadir Therapeutics | Aptadir Therapeutics develops RNA-based therapies for Myelodysplastic Neoplasms. | Biotech | Milan, Italy | Seed | $45.5M | 2026-09-29 | $47.1M | CDP Venture Capital, Angelini Ventures | 1 to 10 | 2024 |
| Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London, United Kingdom | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| Biolevate | Biolevate provides an AI platform that helps life sciences teams run regulated operations with auditable workflows. | Artificial intelligence | Paris, France | Series A | $34.4M | 2026-09-21 | $40.7M | Bpifrance, EQT Ventures | 11 to 50 | 2024 |
| Matisse Pharmaceuticals | Matisse Pharmaceuticals develops therapies for sepsis and septic shock by targeting cytotoxic histones. | Biotech | Geleen, The Netherlands | Series A | $16.0M | 2026-09-17 | $22.0M | Brightlands Venture Partners, Chemelot Ventures, Limburg Business Development Fund (LBDF) | 11 to 50 | 2014 |
| BioFluff | BioFluff creates plant-based fur, shearling, and plush for the fashion, interior, and toy industries. | Biotech | Paris, France | Seed | $2.5M | 2026-09-02 | $3.2M | SOSV, SOSV SF & NY (Fka IndieBio), Joyance Partners +1 | 1 to 10 | 2022 |
| Amyl Therapeutics | Amyl Therapeutics is a preclinical biotechnology company developing immunotherapy for neurodegenerative diseases. | Biotech | Liège, Belgium | Series A | $9.6M | 2026-09-01 | $44.0M | Meusinvest (Noshaq), Sambrinvest, Mérieux Equity Partners +1 | 1 to 10 | 2020 |
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| Pixelgen Technologies | Pixelgen Technologies develops technologies for biomedical research and diagnostics. | Biotech | Stockholm, Sweden | Series B | $15.5M | 2026-08-20 | $43.5M | Industrifonden, Navigare Ventures, Colibri Ventures +1 | 11 to 50 | 2020 |
| Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden, The Netherlands | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen, Germany | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow, United Kingdom | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| NOUS | NOUS develops biotech ingredients for food, beverage, and nutraceutical products. | Biotech | Lomazzo, Italy | Seed | $2.7M | 2026-07-15 | $3.0M | Eatable Adventures | 1 to 10 | 2023 |
| En Carta Diagnostics | En Carta Diagnostics develops molecular diagnostic technologies for detecting DNA and RNA pathogens at the point of care. | Biotech | Paris, France | Seed | $3.4M | 2026-07-10 | $7.3M | CentraleSupélec Venture | 11 to 50 | 2022 |
| Alchemab Therapeutics | Alchemab Therapeutics develops protective antibodies to prevent hard-to-treat diseases. | Biotech | London, United Kingdom | Series A | $33.6M | 2026-07-09 | $151.1M | DCVC, RA Capital Management, DHVC +2 | 51 to 100 | 2019 |
| smartbax | Smartbax develops multi-targeted antibacterial compounds that are potent against multi-drug resistant bacteria. | Biotech | Munich, Germany | Seed | $5.5M | 2026-06-30 | $7.5M | HTGF (High-Tech Gruenderfonds), Boehringer Ingelheim Venture Fund | 1 to 10 | 2021 |
| Automata | Automata provides laboratory automation software and hardware to increase efficiency in scientific workflows. | Artificial intelligence | London, United Kingdom | Series C | $45.0M | 2026-06-25 | $144.8M | Octopus Ventures, Firstminute Capital, Hummingbird Ventures +1 | 101 to 250 | 2015 |
| Graph Therapeutics | Graph Therapeutics uses AI and multi-omics analysis of patient cells to develop precision immunology treatments. | Artificial intelligence | Klosterneuburg, Austria | Seed | $5.0M | 2026-06-22 | $9.4M | SquareOne Venture Capital, Merantix Capital | 1 to 10 | 2024 |
| Apoha | Apoha is a start-up that has not yet publicly launched. | Biotech | London, United Kingdom | Series A | $36.0M | 2026-06-03 | $36.0M | Plug and Play, Innovate UK, Intel Ignite +2 | 1 to 10 | 2021 |
| Imperagen | Imperagen is a biotechnology company that researches enzyme engineering, artificial intelligence, and synthetic biology. | Artificial intelligence | Manchester, United Kingdom | Seed | $6.7M | 2026-05-20 | $11.0M | IQ Capital, Northern Gritstone | 11 to 50 | 2021 |
| Alcolase | Alcolase is a Danish life science start-up developing treatments for alcohol flushing. | Biotech | Copenhagen, Denmark | Seed | $1.7M | 2026-05-18 | $2.6M | Antler | 1 to 10 | 2021 |
Table 1. Biotech startups in Europe: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 2,201.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Cambridge, United Kingdom | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| 2 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 3 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 4 | Basecamp Research | Basecamp Research is a biotechnology company that uses AI and biological data to develop therapeutics. | Artificial intelligence | London, United Kingdom | Series C | $140.0M | 2026-09-23 | $219.9M | True Ventures, redalpine, Hummingbird Ventures +1 | 51 to 100 | 2019 |
| 5 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 6 | Kynexis | Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. | Biotech | Naarden, The Netherlands | Series A | $112.3M | 2026-08-19 | $173.3M | Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures | 11 to 50 | 2023 |
| 7 | ADCendo | ADCendo develops antibody-drug conjugates to target cancers with high unmet medical needs. | Biotech | Copenhagen, Denmark | Series C | $75.0M | 2026-04-14 | $324.6M | RA Capital Management, Novo Holdings, Gilde Healthcare +2 | 51 to 100 | 2017 |
| 8 | Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| 9 | Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 10 | Biorce | Biorce develops a clinical AI assistant that speeds up and lowers the cost of clinical trials. | Artificial intelligence | Barcelona, Spain | Series A | $52.0M | 2026-02-02 | $61.5M | Plug and Play, YZR Capital, Outsized Ventures +1 | 11 to 50 | 2024 |
Table 2. Biotech startups in Europe: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 79 | 4% | 5 | Computomics, smartbax, Tacalyx |
| 2 | Venture Kick | Startup incubator | Schlieren, Switzerland | 46 | 2% | 2 | Adaptyv Biosystems, Genknowme |
| 3 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 30 | 1% | 8 | Bioliberty, Apoha, CellCentric |
| 4 | Bpifrance | Government investment office | Maisons-alfort, France | 23 | 1% | 2 | Biolevate, Standing Ovation |
| 5 | KfW | Government investment office | Frankfurt, Germany | 22 | 1% | ||
| 6 | European Innovation Council | Startup accelerator | Brussels, Belgium | 21 | 1% | 5 | Onego Bio, Cellbox Solutions, Computomics |
| 7 | Sofinnova Partners | Venture capital firm | Paris, France | 16 | 1% | 3 | T-Therapeutics, Mironid, Bon Vivant |
| 8 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 15 | 1% | 1 | FoRx Therapeutics |
| 9 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 14 | 1% | 1 | Kynexis |
| 10 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 14 | 1% | 2 | Windward Bio, ADCendo |
| 11 | SOSV | Venture capital firm | Princeton, United States | 14 | 1% | 3 | Sava Technology, BioFluff, FluoSphera |
| 12 | Andera Partners | Private equity firm | Paris, France | 13 | 1% | 1 | Exciva |
| 13 | Bayern Kapital | Venture capital firm | Landshut, Germany | 13 | 1% | 1 | mbiomics |
| 14 | MassChallenge | Startup accelerator | Boston, United States | 12 | 1% | 1 | Octarine Bio |
| 15 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 11 | 0% | 3 | smartbax, Tacalyx, Brainomix |
Table 3. Biotech startups in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 1,562 | 71% | $24.5B |
| Software | 368 | 17% | $2.2B |
| Artificial intelligence | 213 | 10% | $1.7B |
| Hardware | 98 | 4% | $530.5M |
| Fintech | 31 | 1% | $44.9M |
| Education | 26 | 1% | $389.7M |
| Cybersecurity | 18 | 1% | $31.5M |
| Energy | 16 | 1% | $57.5M |
| Commerce | 8 | 0% | $15.7M |
Table 4. Biotech startups in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United Kingdom | 638 | 29% |
| France | 270 | 12% |
| Germany | 265 | 12% |
| Switzerland | 207 | 9% |
| The Netherlands | 124 | 6% |
| Spain | 103 | 5% |
| Denmark | 86 | 4% |
| Italy | 79 | 4% |
| Sweden | 66 | 3% |
| Belgium | 66 | 3% |
| Ireland | 53 | 2% |
| Austria | 50 | 2% |
Table 6. Biotech startups in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 12 | 4% | $341.2M |
| October 2026 | 23 | 8% | $686.0M |
| September 2026 | 43 | 16% | $489.4M |
| August 2026 | 12 | 4% | $418.9M |
| July 2026 | 14 | 5% | $212.3M |
| June 2026 | 23 | 8% | $539.1M |
| May 2026 | 20 | 7% | $576.7M |
| April 2026 | 21 | 8% | $386.5M |
| March 2026 | 27 | 10% | $339.0M |
| February 2026 | 19 | 7% | $193.0M |
| January 2026 | 27 | 10% | $403.9M |
| December 2025 | 21 | 8% | $314.0M |
| November 2025 | 11 | 4% | $156.5M |
Table 8. Biotech startups in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 241 | 11% | $4.6B |
| 2025 | 274 | 12% | $4.8B |
| 2024 | 268 | 12% | $4.0B |
| 2023 | 204 | 9% | $2.0B |
| 2022 | 194 | 9% | $1.9B |
| 2021 | 167 | 8% | $2.3B |
Table 9. Biotech startups in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 237 | 11% |
| 2020 to 2022 | 489 | 22% |
| 2015 to 2019 | 749 | 34% |
| 2010 to 2014 | 358 | 16% |
| Before 2010 | 349 | 16% |
Table 10. Biotech startups in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 1,085 | 50% |
| 11 to 50 | 901 | 42% |
| 51 to 100 | 105 | 5% |
| 101 to 250 | 43 | 2% |
| 251 to 500 | 11 | 1% |
| 501 to 1,000 | 4 | 0% |
| 1,001 to 5,000 | 4 | 0% |
| 5,001 to 10,000 | 1 | 0% |
| 10,001 or more | 2 | 0% |
Table 11. Biotech startups in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Europe. On 16 November 2026 that is 2,201 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 2,201 rows: 503 have no round amount, 1 no city and 884 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Europe are on the list?
- 2,201, in the file dated 16 November 2026. 273 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 2,201 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.